Synteract is an innovative CRO supporting biotech and pharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies in more than 60 countries, working with more than 26,000 investigative sites and nearly 750,000 patients. It has contributed to more than 240 product approvals. Synteract offers a notable depth of therapeutic expertise in oncology, dermatology, neuro degenerative, as well as pediatrics and rare and orphan.